

Resource Summary Report

Generated by NIF on Sep 19, 2026

reMYND

RRID:SCR_003824

Type: Tool

Proper Citation

reMYND (RRID:SCR_003824)

Resource Information

URL: <http://www.remynd.com/>

Proper Citation: reMYND (RRID:SCR_003824)

Description: Organization that drives the development of disease-modifying treatments against Alzheimer's, Parkinson's, Diabetes and other protein misfolding disorders through two independently managed business units: * Contract Research: The in-vivo Contract Research Organization (CRO) helps its clients to assess the pharmacokinetics and -dynamics of their experimental treatments against Alzheimer's disease. The main focus is on efficacy testing of candidate drugs in reMYND's proprietary Alzheimer mouse models expressing the clinical APP-London allele as single transgene or in combination with clinical alleles of human PS1 and TAU. * Drug Discovery: The Drug Discovery and Development Unit (DDD) focuses on disease-modifying treatments against protein-misfolding disorders, such as Alzheimer's disease (tau), Parkinson's disease (-synuclein), and Diabetes. In addition, reMYND grants licenses and markets commercial kits of RadarScreen, a technology for rapid and cost-effective identification of genotoxic liabilities in early stage drug discovery. reMYND has been substantially supported by grants from IWT and from The Michael J Fox Foundation.

Abbreviations: reMYND

Synonyms: reMYND NV

Resource Type: commercial organization

Keywords: protein misfolding

Related Condition: Alzheimer's disease, Parkinson's disease, Diabetes

Funding: IWT ;
Michael J. Fox Foundation for Parkinson's Research

Resource Name: reMYND

Resource ID: SCR_003824

Alternate IDs: nlx_158130

Record Creation Time: 20220129T080221+0000

Record Last Update: 20260912T195603+0000

Ratings and Alerts

No rating or validation information has been found for reMYND.

No alerts have been found for reMYND.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Albert M, et al. (2019) Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody. Brain : a journal of neurology, 142(6), 1736.